PROF — Profound Medical Corp.

Profound Medical (PROF) Q2 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Orders: Over $3 million.
• Revenue: $2.2 million, unchanged from Q2 2024.
  • Recurring Revenue: $1.6 million.
  • Capital Equipment Sales: $650,000.
• Gross Margin: 73%, up from 64% in Q2 2024.
• Operating Expenses: $15.4 million, compared to $9.3 million in Q2 2024.
• Net Loss: $15.7 million ($0.52 per share), compared to a net loss of $6.9 million ($0.28 per share) in Q2 2024.
• Cash Position: $35.2 million as of June 30, 2025.

2. Strategic Updates and Business Highlights

• Sales Transition: The company is shifting from a placement model to a capital sales model, expecting significant growth in the second half of 2025.
• Sales Pipeline: Approximately 500 prospects with 80 qualified leads in various stages of negotiation and contracting.
• CAPTAIN Trial: Successfully completed recruitment with 212 patients treated, aiming for favorable treatment guidelines and reimbursement coverage.
• TULSA-AI Volume Reduction Software: Pilot launched, expected to streamline BPH procedures to 60-90 minutes, enhancing operational efficiency.
• Clinical Outcomes: Positive initial perioperative outcomes from the CAPTAIN trial presented at the AUA Annual Meeting, indicating TULSA's advantages over robotic surgery.

3. Forward Guidance and Outlook

• Revenue Growth Expectation: Management maintains a target of 70% to 75% revenue growth in 2025 compared to 2024.
• Sales Strategy: Focus on increasing U.S. sites and transitioning to a capital revenue model, with expectations of a shift from recurring to capital revenue dominance.

4. Bad News, Challenges, or Points of Concern

• Revenue Shortfall: Q2 revenues were below expectations due to delays in TULSA-PRO capital sales.
• Increased Operating Expenses: Significant rise in operating expenses, potentially impacting profitability.
• Sales Cycle Complexity: The transition to capital sales involves a complex contracting process with multiple departments, which could delay revenue recognition.
• Market Competition: Ongoing competition in the prostate cancer treatment space, including systemic therapies that may influence physician preferences.

5. Notable Q&A Insights

• Sales Funnel Dynamics: The sales team has been streamlined to enhance efficiency, focusing on organizational selling to multiple hospital departments.
• Feedback on CAPTAIN Trial: Physicians are positively responding to the completion of the trial, which may facilitate greater adoption of TULSA.
• Reimbursement Landscape: Proposed CMS rules favor TULSA's reimbursement structure compared to other BPH procedures, enhancing its market position.
• BPH Module Performance: Early pilot data indicates procedure times are closer to the 60-minute target, with positive feedback from initial users.
• Long-Term Outlook: Management remains optimistic about TULSA's role in prostate cancer treatment, especially as new data and software enhancements are expected to drive adoption.

Overall, while Profound Medical faces challenges in revenue growth and operational expenses, strategic initiatives and positive clinical outcomes position the company for potential future success.